The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH AL 2020 | Targeting T-cell malignancies with CRISPR/Cas9 gene edited universal CAR-T
John DiPersio
• 7 Jul 2020
John DiPersio, MD, PhD, Washington University School of Medicine, Washington, WA, outlines the role of cellular therapies, particularly CRISPR/Cas9 gene-edited universal CAR T-cells, for the treatment of T-cell malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
